Shire sees 23% growth as it eyes $10bn in sales by 2020
This article was originally published in Scrip
Executive Summary
Shire CEO Flemming Ornskov called 2014 a "historic, transformational" year which saw "record progress", and sales climb by 23% to $5.8bn. And 2015 got off to a flying start: within the first few weeks Shire announced its largest acquisition to date and the first approval for a drug to treat binge-eating disorder, Vyvanse.